Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT100 (rhG-CSF) for unexplained recurrent pregnancy loss
2014-000084-40Phase 2Completed
- Sponsor
- Nora Therapeutics, Inc.
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in recurrent miscarriage (RPL) comparing NT100 (rhG-CSF) with Placebo (2 arms). Primary endpoint: Clinical pregnancy rate at Week 20 of gestation. Started Mar 2014; status: completed.
02
Drugs
NT100
03
Conditions
recurrent miscarriage (RPL)
Beyond the preview
Go deeper on 2014-000084-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000084-40.